Coronary artery disease (CAD) is one of the most common causes of death worldwide. In the
last decade, significant advancements in CAD treatment have been made. The existing …

Although traditional renin–angiotensin system antagonists including angiotensin‐converting
enzyme inhibitors and angiotensin receptor blockers have revolutionized the treatment of …

Aims This study aims to investigate the eligibility of the Prospective Comparison of
Angiotensin Receptor–Neprilysin Inhibitor (ARNI) with ACE inhibitor to Determine Impact on …

Heart failure (HF) is a clinical syndrome that results from a structural or functional cardiac
disorder that reduces the ability of the ventricle of the heart to fill with, or eject, blood. It is a …

Objectives: Sacubitril/valsartan was approved recently for the treatment of patients with heart
failure and reduced ejection fraction. We present 6 cases of ventricular arrhythmia, that …

Background Compared with angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers, Sacubitril/Valsartan has been reported to have superior results. However …

Sacubitril/valsartan, a first‐in‐class angiotensin receptor–neprilysin inhibitor (ARNI) inhibits
angiotensin II and neprilysin, enhancing circulating vasoactive peptides. It is recommended …

Aim: To analyse the increasing burden of coronary artery disease (CAD) in tropical and
subtropical belts of the Equator since it remains blurred and carries a grim prognosis …

Objective: Clinical trial data on sacubitril/valsartan are important. Considering that real-world
data have important clinical implications, we aimed to report the efficacy and safety of …